Fred R. Hirsch, MD, PhD

Articles

Dr. Hirsch on the Expansion of Molecular Testing in Lung Cancer

November 12th 2019

Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.

Dr. Hirsch on Value of PD-L1 Testing in Patients With Lung Cancer

September 23rd 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer (IASLC), discusses the value of PD-L1 assays for patients with non–small cell lung cancer. Hirsch shared his during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Hirsch on Importance of Molecular Testing in Lung Cancer

August 5th 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer, discusses the importance of molecular testing for patients with lung cancer.

Dr. Fred Hirsch on Next Steps for Necitumumab in NSCLC

April 19th 2016

Fred R. Hirsch, MD, PhD, professor of medicine and pathology, University of Colorado Cancer Center, CEO, International Association for the Study of Lung Cancer (IASLC), discusses necitumumab for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC).

Dr. Hirsch Discusses the Role of Next-Generation EGFR Inhibitors

August 1st 2014

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.

x